Close Menu

SiMoA

The company sold 2.2 million shares at an average price of $22.73 per share under a $50 million at-the-market equity facility it filed in March 2019.

The company posted Q1 revenues of $12.3 million, up from $7.5 million in Q1 2018 and above the consensus Wall Street estimate of $10.2 million.

They demonstrated the applicability of the Simoa platform for nucleic acid detection, and miRNA detection in particular, as Quanterix prepares to launch a new system.

Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.

The team's dilution experiments suggest Simoa could be thousands of times more sensitive than standard ELISAs in detecting anti-dengue antibodies.

A team led by researchers at the University of Gothenberg have published a study using Quanterix's Simoa technology to measure the brain protein tau in the blood of hockey players to assess brain injury due to concussions.

This article has been updated to include ImmunArray's participation in the program.

A research team at the University of Gothenburg in Sweden is using Quanterix's Single Molecule Array, or Simoa, platform to identify blood biomarkers related to brain injury.

Quanterix said this week that response to the launch last week of its research-use-only automated Single Molecule Array, or Simoa, platform has been enthusiastic – particularly among developers of laboratory-developed tests – and that it will ship the first of its systems to cust

Quanterix this week launched a commercial, research-use-only version of its Single Molecule Array, Simoa, platform.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.